Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer-Reference-Cited by-同舟云学术

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

Published:2018-11-28 Issue:1 Volume:4 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Guarducci Cristina,Bonechi Martina,Benelli Matteo,Biagioni Chiara,Boccalini Giulia,Romagnoli Dario,Verardo Roberto,Schiff Rachel,Osborne C. Kent,De Angelis Carmine,Di Leo Angelo,Malorni Luca,Migliaccio Ilenia

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/s41523-018-0092-4.pdf

Reference47 articles.

1. Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015).

2. Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. New Engl. J. Med. 375, 1925–1936 (2016).

3. Turner, N. C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. New Engl. J. Med. https://doi.org/10.1056/NEJMoa1505270 (2015).

4. Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New Engl. J. Med. 375, 1738–1748 (2016).

5. Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A. & Sutherland, R. L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558–572 (2011).

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-targeting CDK 4/6 and C-MYC/STAT3/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand;Journal of Inorganic Biochemistry;2024-10

2. APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor–induced arrest;Proceedings of the National Academy of Sciences;2024-07-18

3. The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer;Journal of Experimental & Clinical Cancer Research;2024-06-18

4. The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2;2024-05-02

5. The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2;2024-05-02